Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
NCT06573151
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma
Interventions
DRUG:
Selinexor, anti-PD-1 antibody and P-GemOx
Sponsor
Ruijin Hospital